Standard Biotools (LAB) Other Accumulated Expenses (2022 - 2026)

Standard Biotools (LAB) has reported Other Accumulated Expenses for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 66.99% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 66.99% YoY), while the FY2025 annual figure was $1.5 million, down 68.85% from the prior year.
• Other Accumulated Expenses grew to $1.5 million in Q1 2026 per LAB's latest filing, from $1.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $7.3 million in Q3 2024 and bottomed at $714000.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $3.5 million across 5 years, with a median of $3.3 million in 2023.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 917.51% — and 2025, when it plunged 83.63%.
• Standard Biotools' Other Accumulated Expenses stood at $913000.0 in 2022, then soared by 341.73% to $4.0 million in 2023, then increased by 15.5% to $4.7 million in 2024, then tumbled by 68.85% to $1.5 million in 2025, then advanced by 5.79% to $1.5 million in 2026.
• Business Quant data shows LAB's Other Accumulated Expenses at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $2.5 million in Q3 2025.